8-K: Nuwellis Reports Q1 2025 Financial Results, Highlights Pediatric Growth and Expense Reduction

Nuwellis, Inc. announced its first quarter 2025 financial results, showcasing growth in pediatric revenue and a significant reduction in operating expenses.

Summary

• Nuwellis, Inc. reported a 3% increase in revenue for the first quarter of 2025, reaching $1.9 million.
• Pediatric revenue experienced substantial growth, increasing by 38% year-over-year.
• The company achieved a significant reduction in operating expenses, decreasing by 31% or $1.8 million compared to the prior-year quarter.
• Gross margin decreased to 56.0% from 64.1% in the prior-year quarter, attributed to manufacturing variances and inventory adjustments.
• The company's operating loss improved to $3.1 million, compared to $4.7 million in the first quarter of 2024.
• Net loss attributable to common shareholders was $3.0 million, or $0.69 per share, compared to $3.8 million, or $24.11 per share, in the prior-year period.
• As of March 31, 2025, Nuwellis had $2.6 million in cash and cash equivalents and remained debt-free.
• Effective January 1, 2025, CMS reassigned Aquadex to a higher outpatient reimbursement level, increasing the facility fee nearly four-fold to $1,639 per day.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported a net loss, there were positive trends in revenue growth, particularly in the pediatric segment, and a significant reduction in operating expenses. The increased CMS reimbursement is also a positive development.

Positives

• Revenue increased by 3% year-over-year.
• Consumables utilization grew by 4% year-over-year.
• Pediatric revenue increased significantly by 38% year-over-year.
• Operating expenses decreased by 31%, resulting in a $1.8 million reduction.
• CMS reimbursement increased significantly for outpatient Aquadex procedures to $1,639 per day.
• Operating loss improved from $4.7 million to $3.1 million year-over-year.
• The company remains debt-free.

Negatives

• Gross margin decreased to 56.0% from 64.1% in the prior-year quarter due to unfavorable manufacturing variances, lower fixed overhead absorption from reduced production, and an inventory adjustment related to the FlexFlow console.
• Net loss attributable to common shareholders was $3.0 million, or $0.69 per share.

Risks

• The company's future performance is subject to risks detailed in its filings with the Securities and Exchange Commission.
• Unfavorable manufacturing variances and inventory adjustments negatively impacted gross margins.
• The company had $2.6 million in cash and cash equivalents as of March 31, 2025, which may require additional funding in the future.

Future Outlook

The company believes it is well-positioned to expand adoption across both inpatient and outpatient environments in 2025, driven by higher reimbursement rates and a growing base of clinical support.

Management Comments

• John Erb, Chairman of the Board and Interim Chief Executive Officer of Nuwellis, stated that the company is encouraged by the strategic progress being made in expanding access to Aquadex therapy, particularly as more hospitals explore outpatient use.
• John Erb believes that with higher reimbursement rates now in effect and a growing base of clinical support, the company is well-positioned to expand adoption across both inpatient and outpatient environments in 2025.

Industry Context

The increased CMS reimbursement for outpatient Aquadex therapy reflects a broader industry trend towards shifting medical procedures to lower-cost outpatient settings. This aligns with efforts to reduce healthcare costs and improve patient access to care.

Comparison to Industry Standards

• Given Nuwellis' focus on fluid overload and ultrafiltration, comparable companies include those in the dialysis and critical care spaces, such as Baxter International and Fresenius Medical Care, although these are much larger companies.
• The 3% revenue growth is modest compared to some high-growth medical device companies, but the 38% growth in pediatric revenue is a positive sign.
• The reduction in operating expenses is a positive step towards improving profitability, which is a key metric for investors in the medical device industry.

Stakeholder Impact

• Shareholders may be encouraged by the revenue growth and expense reduction, but concerned about the net loss and cash position.
• Employees may be impacted by the reduced staffing levels that contributed to lower operating expenses.
• Customers (hospitals and healthcare providers) may benefit from the increased CMS reimbursement for Aquadex therapy.
• Patients may benefit from increased access to Aquadex therapy in outpatient settings.

Next Steps

• Nuwellis will host a conference call and webcast to discuss its first quarter results and recent business developments.
• The company will continue to focus on expanding access to Aquadex therapy in both inpatient and outpatient settings.

Key Dates

Keywords

Nuwellis, Aquadex, Financial Results, Fluid Overload, Medical Device, Reimbursement, Pediatric Growth, Operating Expenses